GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (HAM:IDP) » Definitions » Accumulated other comprehensive income (loss)

Biogen (HAM:IDP) Accumulated other comprehensive income (loss) : €-148 Mil (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Biogen Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Biogen's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was €-148 Mil.

Biogen's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2023 (€-149 Mil) to Dec. 2023 (€-141 Mil) but then declined from Dec. 2023 (€-141 Mil) to Mar. 2024 (€-148 Mil).

Biogen's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 (€-94 Mil) to Dec. 2022 (€-156 Mil) but then increased from Dec. 2022 (€-156 Mil) to Dec. 2023 (€-141 Mil).


Biogen Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Biogen's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Accumulated other comprehensive income (loss) Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -121.68 -245.78 -94.43 -155.67 -140.94

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -160.65 -159.49 -149.26 -140.94 -147.66

Biogen Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.


Biogen Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Biogen's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (HAM:IDP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (HAM:IDP) » Definitions » Accumulated other comprehensive income (loss)
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (HAM:IDP) Headlines

No Headlines